On April 14, 2025, Hangzhou Fanttest Biotech Co., Ltd. (hereinafter referred to as "Fanttest") announced that its independently developed rapid respiratory diseases combination test kits (6-in-1 and 8-in-1) have successfully get the approval of Hong Kong’s medical regulatory authority and have been officially certified for market launch. Fanttest will now offer more efficient and convenient respiratory pathogen screening solutions for Hong Kong and surrounding regions.
6-in-1 Test Kit
Capable of simultaneously detecting six common respiratory pathogens: COVID-19， Influenza A & B, Respiratory Syncytial Virus (RSV), Adenovirus, and Mycoplasma pneumoniae. Results are available within 15 minutes. Suitable for use in clinics, hospitals, and at-home self-testing scenarios.
8-in-1 Test Kit
In the base of the combination 6-in-1 test, this version additionally detects Human Metapneumovirus and Parainfluenza Virus, offering broader coverage and more precise solutions for differential diagnosis of complex respiratory infections.
This certification marks a significant milestone in the strategic collaboration between Fanttest and Hong Kong partner, TopBio. Leveraging TopBio’s localized services, the product will be rapidly rolled out to public hospitals, private healthcare institutions, and pharmacies across Hong Kong, contributing to the region’s respiratory disease prevention and control efforts.
Hangzhou Fanttest Biotech Co., Ltd (Manufacturer)
Phone: +86-571 86337555
Email: info@fanttest.com
Website: www.fanttest.com
